Young Data analysis and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. operating group of specialists in the fields of malignancy\connected thrombosis/hemostasis, hematology, and oncology discussed key issues related to the use of DOACs in individuals with VTE or AF and malignancy who are at risk of nausea and vomiting and formulated some consensus recommendations. We present these consensus recommendations, which format strategies for the use and management of anticoagulants, including DOACs, in sufferers with VTE or cancers and AF for whom dental medication intake might cause issues. Guidance is supplied on managing sufferers with gastrointestinal blockage or nausea and vomiting that’s caused by cancers treatments or various other cancer\related elements. The recommendations specified within this review give a useful guide for healthcare professionals and can assist in improving the administration of anticoagulation in sufferers with VTE or AF and cancers. Implications for Practice. Direct dental anticoagulants (DOACs) give many advantages over traditional anticoagulants, including simple administration and having less need for regular monitoring. However, the administration of sufferers with a sign for concomitant and anticoagulation cancers, who are in risky of thromboembolic occasions, presents several issues for administering dental therapies, in regards to to the chance of nausea and vomiting particularly. In the lack of solid data from randomized studies and specific suggestions, consensus recommendations had been developed for health care professionals regarding the usage of DOACs in sufferers with cancer, with a concentrate on the administration of sufferers who are in threat of vomiting and nausea. 2018;23:468C473; on November 20 initial released, 2017. Implications for Practice: Malignant gliomas are connected with elevated dangers of both venous thromboses and intracranial hemorrhage, however the extra bleeding risk connected with healing anticoagulation appears appropriate, after treatment of primary tumors specifically. Most sufferers with treated human brain metastasis have a minimal threat of intracranial hemorrhage connected with healing anticoagulation, and low molecular fat heparin may be the recommended agent of preference currently. Patients with neglected human brain metastasis from melanoma, renal cell carcinoma, thyroid cancers, choriocarcinoma, and hepatocellular carcinoma possess an increased propensity for spontaneous intracranial bleeding, and systemic anticoagulation may be contraindicated in the acute environment of venous thromboembolism. Author Efforts Conception/style: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Provision of research material or sufferers: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Collection and/or set up of data: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Data evaluation and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Manuscript composing: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Final acceptance of manuscript: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Disclosures Hanno Riess: Aspen, Bayer, Bristol\Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi\Aventis, Shire (C/A, SAB); Cihan Ay: Pfizer, Bristol\Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Bayer (H); Rupert Bauersachs: Aspen, Bayer, Boehringer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (C/A), Bayer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (SAB); Cecilia Becattini: Bayer Health care, Bristol\Myers Squibb, Pfizer, Daiichi Sankyo (H), Bayer, Boehringer, Pfizer, Daiichi Sankyo (RF); Jan Beyer\Westendorf: Bayer, Boehringer, Pfizer, LEO, Portola, Daiichi Sankyo (H); Francis Cajfinger: Bayer (C/A, SAB), Leo Pharma, Pfizer, Sanofi (otherexpert testimony); Ian Chau: Sanofi Oncology, Eli Lilly & Co., Bristol\Myers Squibb, Merck Clear & Dohme, ATI-2341 Bayer, Roche, Five Perfect Therapeutics (SAB), Eli Lilly & Co., Janssen\Cilag, Sanofi Oncology, Merck\Serono, Novartis (H), Taiho, Pfizer, Amgen, Eli Lilly & Co. (RF); Alexander T. Cohen: Aspen, Bayer, Boehringer\Ingelheim, Bristol\Myers.Cohen, Alok A. the administration and usage of anticoagulants, including DOACs, in sufferers with VTE or AF and cancers for whom dental medication intake may create challenges. Guidance is certainly provided on handling sufferers with gastrointestinal blockage or nausea and throwing up that’s caused by cancers treatments or various other cancer\related elements. The recommendations specified within this review give a useful guide for healthcare professionals and can assist in improving the administration of anticoagulation in sufferers with VTE or AF and cancers. Implications for Practice. Direct dental anticoagulants (DOACs) give many advantages over traditional anticoagulants, including simple administration and having less need for regular monitoring. Nevertheless, the administration of sufferers with a sign for anticoagulation and concomitant cancers, who are in risky of thromboembolic occasions, presents several issues for administering dental therapies, particularly in regards to to the chance of nausea and throwing up. In the lack of solid data from randomized studies and specific suggestions, consensus recommendations had been developed for health care professionals regarding the usage of DOACs in sufferers with cancer, using a concentrate on the administration of sufferers who are in threat of nausea and throwing up. 2018;23:468C473; initial released on November 20, 2017. Implications for Practice: Malignant gliomas are connected with elevated dangers of both venous thromboses and intracranial hemorrhage, however the extra bleeding risk connected with healing anticoagulation appears appropriate, specifically after treatment of major tumors. Most individuals with treated mind metastasis have a minimal threat of intracranial hemorrhage connected with restorative anticoagulation, and low molecular pounds heparin happens to be the most well-liked agent of preference. Patients with neglected mind metastasis from melanoma, renal cell carcinoma, thyroid tumor, choriocarcinoma, and hepatocellular carcinoma possess an increased propensity for spontaneous intracranial bleeding, and systemic anticoagulation could be contraindicated in the severe placing of venous thromboembolism. Writer Contributions Conception/style: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Provision of research material or individuals: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Collection and/or set up of data: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Data evaluation and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Manuscript composing: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Final authorization of manuscript: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Disclosures Hanno Riess: Aspen, Bayer, Bristol\Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi\Aventis, Shire (C/A, SAB); Cihan Ay: Pfizer, Bristol\Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Bayer (H); Rupert Bauersachs: Aspen, Bayer, Boehringer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (C/A), Bayer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (SAB); Cecilia Becattini: Bayer Health care, Bristol\Myers Squibb, Pfizer, Daiichi Sankyo (H), Bayer, Boehringer, Pfizer, Daiichi Sankyo (RF); Jan Beyer\Westendorf: Bayer, Boehringer, Pfizer, LEO, Portola, Daiichi Sankyo (H); Francis Cajfinger: Bayer (C/A, SAB), Leo Pharma, Pfizer, Sanofi (otherexpert testimony); Ian Chau: Sanofi Oncology, Eli Lilly & Co., Bristol\Myers Squibb, Merck Clear & Dohme, Bayer, Roche, Five Primary Therapeutics (SAB), Eli Lilly & Co., Janssen\Cilag, Sanofi Oncology, Merck\Serono, Novartis (H), Taiho, Pfizer, Amgen, Eli Lilly & Co. (RF); Alexander T. Cohen: Aspen, Bayer, Boehringer\Ingelheim, Bristol\Myers Squibb, CSL Behring, Daiichi\Sankyo, GlaxoSmithKline, GLG, Guidepoint Global, Johnson and Johnson, Leo.Khorana, Anthony Maraveyas, Marcos Renni, Annie M. the foundation of this proof, an international operating group of specialists in the areas of tumor\connected thrombosis/hemostasis, hematology, and oncology talked about key issues linked to the usage of DOACs in individuals with VTE or AF and tumor who are in threat of nausea and throwing up and created some consensus suggestions. We present these consensus suggestions, which outline approaches for the utilization and administration of anticoagulants, ATI-2341 including DOACs, in individuals with VTE or AF and tumor for whom dental medication intake may cause challenges. Guidance can be provided on controlling individuals with gastrointestinal blockage or nausea and throwing up that’s caused by cancers treatments or additional cancer\related elements. The recommendations defined with this review give a useful research for healthcare professionals and can assist in improving the administration of anticoagulation in individuals with VTE or AF and tumor. Implications for Practice. Direct dental anticoagulants (DOACs) present many advantages over traditional anticoagulants, including simple administration and having less need for regular monitoring. Nevertheless, the administration of individuals with a sign for anticoagulation and concomitant tumor, who are in risky of thromboembolic occasions, presents several problems for administering dental therapies, particularly in regards to to the chance of nausea and throwing up. In the lack of solid data from randomized tests and specific recommendations, consensus recommendations had been developed for health care professionals regarding the usage of DOACs in individuals with cancer, having a concentrate on the administration of individuals who are in threat of nausea and throwing up. 2018;23:468C473; 1st released on November 20, 2017. Implications for Practice: Malignant gliomas are connected with improved dangers of both venous thromboses and intracranial hemorrhage, however the extra bleeding risk connected with restorative anticoagulation appears suitable, specifically after treatment of major tumors. Most individuals with treated mind metastasis have a minimal threat of intracranial hemorrhage connected with restorative anticoagulation, and low molecular pounds heparin happens to be the most well-liked agent of preference. Patients with neglected mind metastasis from melanoma, renal cell carcinoma, thyroid tumor, choriocarcinoma, and hepatocellular carcinoma possess an increased propensity for spontaneous intracranial bleeding, and systemic anticoagulation could be contraindicated in the severe placing of venous thromboembolism. Writer Contributions Conception/style: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Provision of research material or individuals: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Collection and/or set up of data: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Data evaluation and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Manuscript composing: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Final authorization of manuscript: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Little Disclosures Hanno Riess: Aspen, Bayer, Bristol\Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi\Aventis, Shire (C/A, SAB); Cihan Ay: Pfizer, Bristol\Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Bayer (H); Rupert Bauersachs: Aspen, Bayer, Boehringer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (C/A), Bayer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (SAB); Cecilia Becattini: Bayer Health care, Bristol\Myers Squibb, Pfizer, Daiichi Sankyo (H), Bayer, Boehringer, ATI-2341 Pfizer, Daiichi Sankyo (RF); Jan Beyer\Westendorf: Bayer, Boehringer, Pfizer, LEO, Portola, Daiichi Sankyo (H); Francis Cajfinger: Bayer (C/A, SAB), Leo Pharma, Pfizer, Sanofi.Cohen, Alok A. data for the occurrence and administration of tumor\connected nausea and throwing up and the existing evidence and assistance relating to the usage of DOACs in individuals with cancer. Based on this evidence, a global working band of specialists in the areas of tumor\connected thrombosis/hemostasis, hematology, and oncology talked about key issues linked to the usage of DOACs in individuals with VTE or AF and tumor who are in threat of nausea and throwing up and created some consensus suggestions. We present these consensus suggestions, which outline approaches for the utilization and administration of anticoagulants, including DOACs, in sufferers with VTE or AF and cancers for whom dental medication intake may create challenges. Guidance is normally provided on handling sufferers with gastrointestinal blockage or nausea and throwing up that’s caused by cancer tumor treatments or various other cancer\related elements. The recommendations specified within this review give a useful guide for healthcare professionals and can assist in improving the administration of anticoagulation in sufferers with VTE or AF and cancers. Implications for Practice. Direct dental anticoagulants (DOACs) give many advantages over traditional anticoagulants, including simple administration and having less need for regular monitoring. Nevertheless, the administration of sufferers with a sign for anticoagulation and concomitant cancers, who are in risky of thromboembolic occasions, presents several issues for administering dental therapies, particularly in regards to to the chance of nausea and throwing up. In the lack of sturdy data from randomized studies and specific suggestions, consensus recommendations had been developed for health care professionals regarding the usage of DOACs in sufferers with cancer, using a concentrate on the administration of sufferers who are in threat of nausea and throwing up. 2018;23:468C473; initial released on November 20, 2017. Implications for Practice: Malignant gliomas are connected Rabbit polyclonal to MTOR with elevated dangers of both venous thromboses and intracranial hemorrhage, however the extra bleeding risk connected with healing anticoagulation appears appropriate, specifically after treatment of principal tumors. Most sufferers with treated human brain metastasis have a minimal threat of intracranial hemorrhage connected with healing anticoagulation, and low molecular fat heparin happens to be the most well-liked agent of preference. Patients with neglected human brain metastasis from melanoma, renal cell carcinoma, thyroid cancers, choriocarcinoma, and hepatocellular carcinoma possess an increased propensity for spontaneous intracranial bleeding, and systemic anticoagulation could be contraindicated in the severe setting up of venous thromboembolism. Writer Contributions Conception/style: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Provision of research material or sufferers: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Collection and/or set up of data: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Data evaluation and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Manuscript composing: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Final acceptance of manuscript: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Disclosures Hanno Riess: Aspen, Bayer, Bristol\Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi\Aventis, Shire (C/A, SAB); Cihan Ay: Pfizer, Bristol\Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Bayer (H); Rupert Bauersachs: Aspen, Bayer, Boehringer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (C/A), Bayer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (SAB); Cecilia Becattini: Bayer Health care, Bristol\Myers Squibb, Pfizer, Daiichi Sankyo (H), Bayer, Boehringer, Pfizer, Daiichi Sankyo (RF); Jan Beyer\Westendorf: Bayer,.Cohen, Alok A. and ATI-2341 vomiting and created some consensus suggestions. We present these consensus suggestions, which outline approaches for the utilization and administration of anticoagulants, including DOACs, in sufferers with VTE or AF and cancers for whom dental medication intake may create challenges. Guidance is normally provided on handling sufferers with gastrointestinal blockage or nausea and throwing up that’s caused by cancer tumor treatments or various other cancer\related elements. The recommendations specified within this review give a useful guide for healthcare professionals and can assist in improving the administration of anticoagulation in sufferers with VTE or AF and cancers. Implications for Practice. Direct dental anticoagulants (DOACs) give many advantages over traditional anticoagulants, including simple administration and having less need for regular monitoring. Nevertheless, the administration of sufferers with a sign for anticoagulation and concomitant cancers, who are in risky of thromboembolic occasions, presents several issues for administering dental therapies, particularly in regards to to the chance of nausea and throwing up. In the lack of sturdy data from randomized studies and specific suggestions, consensus recommendations had been developed for health care professionals regarding the usage of DOACs in sufferers with cancer, using a concentrate on the administration of sufferers who are in threat of nausea and throwing up. 2018;23:468C473; initial released on November 20, 2017. Implications for Practice: Malignant gliomas are connected with elevated dangers of both venous thromboses and intracranial hemorrhage, however the extra bleeding risk connected with healing anticoagulation appears appropriate, specifically after treatment of principal tumors. Most sufferers with treated human brain metastasis have a minimal threat of intracranial hemorrhage connected with healing anticoagulation, and ATI-2341 low molecular fat heparin happens to be the most well-liked agent of preference. Patients with neglected human brain metastasis from melanoma, renal cell carcinoma, thyroid cancers, choriocarcinoma, and hepatocellular carcinoma possess an increased propensity for spontaneous intracranial bleeding, and systemic anticoagulation could be contraindicated in the severe setting up of venous thromboembolism. Writer Contributions Conception/style: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Provision of research material or sufferers: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Collection and/or set up of data: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Data evaluation and interpretation: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Manuscript composing: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Final acceptance of manuscript: Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer\Westendorf, Francis Cajfinger, Ian Chau, Alexander T. Cohen, Alok A. Khorana, Anthony Maraveyas, Marcos Renni, Annie M. Teen Disclosures Hanno Riess: Aspen, Bayer, Bristol\Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi\Aventis, Shire (C/A, SAB); Cihan Ay: Pfizer, Bristol\Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Bayer (H); Rupert Bauersachs: Aspen, Bayer, Boehringer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (C/A), Bayer, Bristol\Myers Squibb, Pfizer, Daiichi\Sankyo (SAB); Cecilia Becattini: Bayer Health care, Bristol\Myers Squibb, Pfizer, Daiichi Sankyo (H), Bayer, Boehringer, Pfizer, Daiichi Sankyo (RF); Jan.